Oh Plodge. One could pick an arbitrary timescale, as you do, and...

Oh Plodge.

One could pick an arbitrary timescale, as you do, and indeed call MSB trolls idiots on the same arbitrary measure you use for idiocy. For example a simple YTD return on MSB ownership. 'Idiocy' that far exceeds that of CYP holders, if that indeed if that your measure. It is of course, excuse the pun, an idiotic measure of idiocy:



No. The way the MSB trolls have been idiots (his term not mine moderators - you are never slow to have things moderated you don't like yourself, despite whining when others have your vitriol moderated) is in the ignorance they post - the actual same criticism above in response to the usual uninformed (and acrimonious) trolling of CYP threads. You yourself have been caught out many times simply not reading the very CYP ASX releases you (incorrectly) criticise. Some doozies in trial criticisms. Cash flow errors. Etc, etc. Gavin has shown some impressive ineptitude in presuming IPSC manufacturing was some sort of unknown, dangerous wilderness yet explored, when the FDA has actually approved the manufacturing of induced pluripotent stem cells (iPSCs) for various clinical applications, including cell therapies for Parkinson's disease and ALS - see for example, XellSmart Biopharmaceutical's IND or Cellino's FDA Advanced Manufacturing Technology (AMT) designation.

You at least know of Cynata's relationship with FujiFilm Cellular Dynamics - that ignoramus clearly did not - and how FCDI offers world-leading iPSC-derived cell therapeutic GMP designated manufacturing facilities and its long and varied regulatory submission experience across a host of regulators and bodies that oversea cellular manufacturing processes. You will of course know that FujiFilm, has collaborated with companies like BlueRock Therapeutics and Century Therapeutics to develop iPSC-derived cell therapies that went on to gain FDA clearance.

Your feeble throwing up of 'the share price drops => ergo anyone invested is an idiot' argument really shows the desperation of trolls trying to disparage CYP. Troll away, and I and others will point out the ignorance/flaws, which we are entitled to do on a public forum. Meanwhile, more pertinent to the actual discussion of this thread, I, like you, await the feedback on MSB's (overdue) Type B meeting with the FDA, regards its accelerated approval Revascor in heart disease treatment - the implications for both MSB (and CYP's) share price obvious.